Spondyloarthritis & psoriatic arthritis
The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis
Authors' conclusion
In this r-axSpA cohort identified using phenotyping methods, TNFi use versus non-use had a lower risk of incident CVD.
Study context
- Population
- Individuals with radiographic axial spondyloarthritis (r-axSpA) in a Veterans Affairs database, 2002–2019 (mean age 63.4 years, 94 % male)at baseline
- Participants
- 26,928 individuals
- Exposure
- Tumor necrosis factor inhibitor (TNFi) use vs non-use
- TNFi usersn = 3,633
- Non-usersn = 23,295reference
- Outcome
- Incident CVD (ICD codes for coronary artery disease, MI or stroke)
Methodological detailsVeterans Affairs database, time-varying exposure, Cox models with inverse probability weights, phenotyping-identified cohort
- Veterans Affairs database
- Time-varying exposure
- Cox models with inverse probability weights
- Phenotyping-identified cohort
Main finding
As reported in the abstract
Incident CVD (coronary artery disease, MI or stroke) · mean follow-up 3.3 ± 4.2 years
Observational data: associations, not effects.
Further findings
Incident CVD in two time periods separately (2002-2010, 2011-2019)
- TNFi use vs non-use associated with lower risk of incident CVD in the two time periods separately
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis. Semin Arthritis Rheum. Published 2 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →